Current staging of renal cell carcinoma

Urologic Clinics of North America

Volumn 30, Issue 3, 2003, Pages 481-497

  Leibovich, Bradley C ^a,b   Pantuck, Allan J ^a   Bui, Matthew H T ^a   Ryu Han, Ken ^a   Zisman, Amnon ^a   Figlin, Robert ^a   Belldegrun, Arie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAMNESIS; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER STATISTICS; CLINICAL FEATURE; DISEASE MARKER; HUMAN; KIDNEY CARCINOMA; LABORATORY DIAGNOSIS; METASTASIS; MOLECULAR BIOLOGY; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 0042821697     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(03)00029-6     Document Type: Review

References (119)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611-23.
3. Devesa SS, Silverman DT, McLaughlin JK, et al. Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control 1990;1:133-41.
4. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999;161:381-6.
5. Thrasher J, Paulson D. Prognostic factors in renal cancer. Urol Clin North Am 1993;20:247-62.
6. Flocks RH, Kadesky M. Malignant neoplasms of the kidney: analysis of 353 patients followed 5 years or more. J Urol 1958;79:196-201.
7. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
8. Sobin L, Wittekind C. TNM classification of malignant tumors. 5th edition. New York: International Union Against Cancer; 1997.
9. Basil B, Dosoretz DE, Prout GR Jr. Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol 1985;134:450-4.
10. Hofmockel G, Tsatalpas P, Muller H, et al. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer 1995;76:296-306.
11. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: workgroup no. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:992-3.
12. Guinan P, Frank W, Saffrin R, et al. Staging and survival of patients with renal cell carcinoma. Semin Surg Oncol 1994;10:47-50.
13. Hermanek P, Schrott KM. Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol 1990;144:238-41.
14. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163:1090-5.
15. Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999;162:1277-81.
16. Kinouchi T, Saiki S, Meguro N, et al. Impact of tumor size on the clinical outcomes of patients with Robson stage I renal cell carcinoma. Cancer 1999;85:689-95.
17. Gettman MT, Blute ML, Spotts B, et al. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001;91:354-61.
18. Bell E. Classification of renal tumors with observations on frequency of various types. J Urol 1938;39:238-43.
19. Grignon DJ, Ayala AG, el-Naggar A, et al. Renal cell carcinoma: a clinicopathologic and DNA flow cytometric analysis of 103 cases. Cancer 1989;64:2133-40.
20. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999;162:1930-3.
21. Lau WK, Cheville JC, Blute ML, et al. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 2002;59:532-7.
22. Zisman A, Pantuck AJ, Chao D, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm better correlates with clinical outcome. J Urol 2001;166:54-8.
23. Green LK, Ayala AG, Ro JY, et al. Role of nuclear grading in stage I renal cell carcinoma. Urology 1989;34:310-5.
24. Medeiros L, Gelb A, Weiss L. Renal cell carcinoma: prognostic significance of morphologic parameters in 121 cases. Cancer 1988;61:1639-51.
25. Sosa RE, Muecke EC, Vaughan ED Jr, et al. Renal cell carcinoma extending into the inferior vena cava: the prognostic significance of the level of vena caval involvement. J Urol 1984;132:1097-100.
26. Cherrie RJ, Goldman DG, Lindner A, et al. Prognostic implications of vena caval extension of renal cell carcinoma. J Urol 1982;128:910-2.
27. Neves RJ, Zincke H. Surgical treatment of renal cancer with vena cava extension. Br J Urol 1987;59:390-5.
28. Glazer AA, Novick AC. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol 1996;155:448-50.
29. Hatcher PA, Anderson EE, Paulson DF, et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 1991;145:20-3.
30. Kuczyk MA, Bokemeyer C, Kohn G, et al. Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer. Br J Urol 1997;80:18-24.
31. Zisman A, Wieder JA, Pantuck A, et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy, and response to immunotherapy. J Urol 2003;169:909-16.
32. Tsui KH, Shvarts O, Barbaric Z, et al. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J Urol 2000;163:437-41.
33. Kletscher BA, Qian J, Bostwick DG, et al. Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol 1996;155:1844-6.
34. Fuhrman S, Lasky C, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
35. Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. Cancer 1971;28:1165-77.
36. Hand J, Broders A. Carcinoma of the kidney: the degree of malignancy in relation to factors bearing on prognosis. J Urol 1932;28:199-216.
37. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002;26:281-91.
38. Moch H, Gasser T, Amin MB. et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89:604-14.
39. Medeiros LJ, Jones EC, Aizawa S, et al. Grading of renal cell carcinoma: workgroup no. 2. Union Internationale Contre le Cancer and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:990-1.
40. Lohse CM, Blute ML, Zincke H, et al. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol 2002;118:877-86.
41. Bielsa O, Lloreta J, Gelabert-Mas A. Cystic renal cell carcinoma: pathological features, survival and implications for treatment. Br J Urol 1998;82:16-20.
42. Corica FA, Iczkowski KA, Cheng L, et al. Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup. J Urol 1999;161:408-11.
43. Renshaw AA, Richie JP. Subtypes of renal cell carcinoma: different onset and sites of metastatic disease. Am J Clin Pathol 1999;111:539-43.
44. Amin MB, Corless CL, Renshaw AA, et al. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 1997;21:621-35.
45. Kattan MW, Reuter V, Motzer RJ, et al. A post-operative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63-7.
46. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997;10:537-44.
47. Lindor NM, Dechet CB, Greene MH, et al. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test 2001;5:101-6.
48. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612-24.
49. Kennedy SM, Merino MJ, Linehan WM, et al. Collecting duct carcinoma of the kidney. Hum Pathol 1990;21:449-56.
50. Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma: the seventh sickle cell nephropathy. Am J Surg Pathol 1995;19:1-11.
51. Chao D, Zisman A, Pantuck AJ, et al. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 2002;167:71-4.
52. Goldstein NS. The current state of renal cell carcinoma grading: Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:977-80.
53. Tomera KM, Farrow GM, Lieber MM. Sarcomatoid renal carcinoma. J Urol 1983;130:657-9.
54. Oda H, Machinami R. Sarcomatoid renal cell carcinoma: a study of its proliferative activity. Cancer 1993;71:2292-8.
55. Sella A, Logothetis CJ, Ro JY, et al. Sarcomatoid renal cell carcinoma: a treatable entity. Cancer 1987;60:1313-8.
56. Farrow GM, Harrison EGJ, Utz DC. Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. Cancer 1968;22:545-63.
57. Ro JY, Ayala AG, Sella A, et al. Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer 1987;59:516-26.
58. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001;25:75-84.
59. Cheville JC, Blute ML, Zincke H, et al. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol 2001;166:453-6.
60. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN score. J Urol 2002;168:2395-400.
61. Leibovitch I, Lev R, Mor Y, et al. Extensive necrosis in renal cell carcinoma specimens: potential clinical and prognostic implications. Isr Med Assoc J 2001;3:563-5.
62. Citterio G, Di Lucca G, Scaglietti U, et al. Reduction of brain metastasis following immunotherapy with interleukin-2 for stage IV renal cell cancer. Acta Oncol 1997;36:228.
63. Fallick ML, McDermott DF, LaRock D, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997;158:1691-5.
64. Mani S, Todd MB, Katz K, et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995;154:35-40.
65. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649-57.
66. deKernion J, Ramming K, Smith R. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978;120:148-52.
67. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-3.
68. Klugo M, Detmers M, Stiles R, et al. Aggressive versus conservative management of stage IV renal cell carcinoma. J Urol 1977;118:244-6.
69. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376-9.
70. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
71. Homma Y, Kawabe K, Kitamura T, et al. Increased incidental detection and reduced mortality in renal cancer - recent retrospective analysis at eight institutions. Int J Urol 1995;2:77-80.
72. Konnak JW, Grossman HB. Renal cell carcinoma as an incidental finding. J Urol 1985;134:1094-6.
73. Thompson IM, Peek M. Improvement in survival of patients with renal cell carcinoma - the role of the serendipitously detected tumor. J Urol 1988;140:487-90.
74. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998;51:203-5.
75. Mevorach RA, Segal AJ, Tersegno ME, et al. Renal cell carcinoma: incidental diagnosis and natural history. Review of 235 cases. Urology 1992;39:519-22.
76. Tsui KH, Shvarts O, Smith RB, et al. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000;163:426-30.
77. Srigley JR, Hutter RV, Gelb AB, et al. Current prognostic factors - renal cell carcinoma: work-group no. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:994-6.
78. Bonsib SM. Risk and prognosis in renal neoplasms: a pathologist's prospective. Urol Clin North Am 1999;26:643-60.
79. Shishikura Y, Suzuki M. Clinicopathologic study of 97 cases of small renal cell carcinomas using DNA flow cytometric analyses. Pathol Int 1996;46:947-52.
80. Srigley JR, Eble JN. Collecting duct carcinoma of kidney. Semin Diagn Pathol 1998;15:54-67.
81. Di Silverio F, Casale P, Colella D, et al. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer 2000;88:835-43.
82. Pich A, Chiusa L, Margaria E. Prognostic relevance of AgNORs in tumor pathology. Micron 2000;31:133-41.
83. Gelb AB. Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (U1CC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:981-6.
84. Delahunt B, Ribas JL, Nacey JN, et al. Nucleolar organizer regions and prognosis in renal cell carcinoma. J Pathol 1991;163:31-7.
85. Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol 1998;15:68-76.
86. Tannapfel A, Hahn HA, Katalinic A, et al. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996;77:164-71.
87. Yasunaga Y, Shin M, Miki T, et al. Prognostic factors of renal cell carcinoma: a multivariate analysis. J Surg Oncol 1998;68(Suppl):11-8.
88. Yang AH, Wang TY, Liu HC. Comparative study of the prognostic value of nuclear grade and silver-binding nucleolar organizer region in renal cell carcinomas. J Pathol 1992;166:157-61.
89. Jochum W, Schroder S, al-Taha R, et al. Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinomas: a clinicopathologic study of 58 patients using mitotic count, MIB-1 staining, and DNA cytophotometry. Cancer 1996;77:514-21.
90. Onda H, Yasuda M, Serizawa A, et al. Clinical outcome in localized renal cell carcinomas related to immunoexpression of proliferating cell nuclear antigen, Ki-67 antigen, and tumor size. Oncol Rep 1999;6:1039-43.
91. Rioux-Leclercq N, Turlin B, Bansard J, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000;55:501-5.
92. Aaltomaa S, Lipponen P, Ala-Opas M, et al. Prognostic value of Ki-67 expression in renal cell carcinomas. Eur Urol 1997;31:350-5.
93. Gelb AB, Sudilovsky D, Wu CD, et al. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer 1997;80:1768-75.
94. Morell-Quadreny L, Clar-Blanch F, Fenollosa-Enterna B, et al. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in renal cell carcinoma. Anticancer Res 1998;18:677-82.
95. Fischer C, Georg C, Kraus S, et al. CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res 1999;19:1513-7.
96. Moch H, Sauter G, Gasser TC, et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol Res 1997;25(Suppl 1):S25-30.
97. Bot FJ, Godschalk JC, Krishnadath KK, et al. Prognostic factors in renal cell carcinoma: immunohistochemical detection of p53 protein versus clinicopathological parameters. Int J Cancer 1994;57:634-7.
98. Hofmockel G, Wittmann A, Dammrich J, et al. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res 1996;16:3807-11.
99. Sejima T, Miyagawa I. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma. Eur Urol 1999;35:242-8.
100. Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 1995;55:658-62.
101. Paraf F, Gogusev J, Chretien Y, et al. Expression of bcl-2 oncoprotein in renal cell tumours. J Pathol 1995;177:247-52.
102. Huang A, Fone PD, Gandour-Edwards R, et al. Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma. J Urol 1999;162:610-3.
103. Vasavada SP, Novick AC, Williams BR. p53, bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51:1057-61.
104. Aaltomaa S, Lipponen P, Ala-Opas M, et al. Expression of cyclins A and D and p21 (waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer 1999;80:2001-7.
105. Grankvist K, Ljungberg B, Rasmuson T. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal cell carcinoma. Int J Cancer 1997;74:233-6.
106. Shimazui T, Bringuier PP, van Berkel H, et al. Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer 1997;74:523-8.
107. Liao SY, Aurelio ON, Jan K, et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997;57:2827-31.
108. Opavsky R, Pastorekova S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996;33:480-7.
109. Murakami Y, Kanda K, Tsuji M, et al. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 1999;83:743-7.
110. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81:741-6.
111. Durrbach A, Angevin E, Poncet P, et al. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro. Cancer Gene Ther 1999;6:564-71.
112. Li G, Passebosc-Faure K, Lambert C, et al. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells. Clin Cancer Res 2001;7:89-92.
113. Oosterwijk E, Debruyne FM. Radiolabeled monoclonal antibody G250 in renal cell carcinoma. World J Urol 1995;13:186-90.
114. Oosterwijk E, Debruyne FM, Schalken JA. The use of monoclonal antibody G250 in the therapy of renal cell carcinoma. Semin Oncol 1995;22:34-41.
115. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998;4:2729-39.
116. Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-7.
117. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 1995;46:27-30.
118. Pantuck AJ, Zisman A, Rauch MK, et al. Incidental renal tumors. Urology 2000;56:190-6.
119. Zisman A, Pantuck AJ, Dorey F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol 2002;20:1368-74.